Patients accept therapy using embryonic stem cells for Parkinson's disease: a discrete choice experiment.

"Declarations Competing interestsKarin Schölin Bywall, Jennifer Drevin, Catharina Groothuis-Oudshoorn, Jorien Veldwijk, Trinette van Vliet, Elena Jiltsova, Mats Hansson, and Jennifer Viberg Johansson declare no conflict of interests. Dag Nyholm has received compensation for consultancies and/or lecturing from AbbVie, Britannia, NeuroDerm, NordicInfu Care, Sensidose and Stada. Hakan Widner has received compensation for education activities from pharmaceutical companies (Bristol Meyer Squibb, Abbott, Abbvie) and performed clinical studies with Herantis Pharma Y/O, Renishaw Ltd., and served as advisor to Novo Nordisk A/S on the use of pluripotent stem cells for clinical use in humans. Ethics approval and consent to participateThis study was approved by the Swedish Ethical Review Authority (Etikprövningsmyndigheten, dnr 2019–06539). All participants provided informed consent to participate in the study. Data are presented in such a way that no individual can be identified. All research was carried out in accordance with relevant national and international guidelines and regulations. Consent for publicationNot applicable. Competing interests Karin Schölin Bywall, Jennifer Drevin, Catharina Groothuis-Oudshoorn, Jorien Veldwijk, Trinette van Vliet, Elena Jiltsova, Mats Hansson, and Jennifer Viberg Johansson declare no conflict of interests. Dag Nyholm has received compensation for consultancies and/or lecturing from AbbVie, Britannia, NeuroDerm, NordicInfu Care, Sensidose and Stada. Hakan Widner has received compensation for education activities from pharmaceutical companies (Bristol Meyer Squibb, Abbott, Abbvie) and performed clinical studies with Herantis Pharma Y/O, Renishaw Ltd., and served as advisor to Novo Nordisk A/S on the use of pluripotent stem cells for clinical use in humans."

"Funding This study was supported by Vinnova Project CAMP (Contract no. 2017–02130) and Swelife-ATMP, a common investment of Vinnova, Formas, and the Swedish Energy Agency (Contract no. 2017–02453). HW has received support for the study from the ALF system (Academic Learning Grants #43307) and Multipark (Strategic Research Initiative). Open access funding provided by Uppsala University."